A stock’s 52-week high and low prices can offer a wealth of information about its current standing and prospective future performance. Lineage Cell Therapeutics Inc’s current trading price is -68.68% away from its 52-week high, while its distance from the 52-week low is 4.84%. The stock’s price range for this time frame has been between $0.48 and $1.61. The trading volume of the company’s shares in the Healthcare reached around 1.1 million for the day, which was evidently lower than the average daily volume of 1.73 million over the last three months.
Lineage Cell Therapeutics Inc’s stock has had a tumultuous market performance. The 1-year high for the company’s stock was $1.61 on 03/28/24, and the lowest price during the same period was recorded at $0.48 on 12/17/24.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
How Financial Performance Impacts Market Capitalization
Lineage Cell Therapeutics Inc (LCTX) has experienced a quarterly decline of -41.48% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 111.15M and boasts a workforce of 75 employees.
The Role of Moving Averages and Trading Volume in Technical Analysis
Based on Barchart.com data, the company’s moving average over the 100-day period was 0.8012, with a change in price of -0.3892. Similarly, Lineage Cell Therapeutics Inc recorded 1,270,665 in trading volume during the last 100 days, posting a change of -43.46%.
How LCTX’s Debt-to-Equity Ratio Affects Financial Health
A company’s financial condition and market reputation can be evaluated using the debt-to-equity (D/E) ratio. This ratio, calculated by dividing a company’s total liabilities by its shareholders’ equity, indicates the proportion of debt a company employs to back its assets in relation to its shareholders’ equity. At the time of writing, the total D/E ratio for LCTX stands at 0.04. Similarly, the long-term debt-to-equity ratio is also 0.02.
LCTX Stock Stochastic Average
The raw stochastic average for Lineage Cell Therapeutics Inc over the last 50 days is presently at 5.19%. This reflects a drop from the raw stochastic average of the previous 20 days, which was noted at 18.27%. Further, the company’s Stochastic %K and %D values for the last 20 days were 33.43% and 41.75%, respectively.
LCTX Stock Price Performance Analysis
Investors’ outlook regarding the stock price performance over the year has been a mixed bag, with a range of optimism to pessimism depending on their perspective. This year’s metric has recorded a Price decrease of -53.73%. However, over the past six months, we’ve seen a stronger performance of -51.04%. The price of LCTX leaped by -12.13% over the last 30 days. And in the last five days, it has surged by 0.56%.
